SANIONA
Saniona is a research and development company with low burn rate, a world class team and high ambitions.
SANIONA
Industry:
Biotechnology
Founded:
2011-01-01
Address:
Ballerup, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.saniona.com
Total Employee:
11+
Status:
Active
Contact:
+45 70 705 225
Email Addresses:
[email protected]
Total Funding:
83.97 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Employees Featured
Founder
Stock Details
Investors List
Fourth Swedish National Pension Fund
Fourth Swedish National Pension Fund investment in Post-IPO Equity - Saniona
Pontifax
Pontifax investment in Post-IPO Equity - Saniona
Andra AP-fonden
Andra AP-fonden investment in Post-IPO Equity - Saniona
Third Swedish National Pension Fund
Third Swedish National Pension Fund investment in Post-IPO Equity - Saniona
New Leaf Venture Partners
New Leaf Venture Partners investment in Post-IPO Equity - Saniona
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Saniona
Innovation Fund Denmark
Innovation Fund Denmark investment in Grant - Saniona
Nice & Green SA
Nice & Green SA investment in Convertible Note - Saniona
Australian Research Council
Australian Research Council investment in Grant - Saniona
Innovation Fund Denmark
Innovation Fund Denmark investment in Grant - Saniona
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-15 | Saniona appoints Wendy Dwyer as Chief Business Officer |
Official Site Inspections
http://www.saniona.com Semrush global rank: 6.32 M Semrush visits lastest month: 1.14 K
- Host name: linux18.curanet.dk
- IP address: 185.21.41.142
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Saniona"
Saniona - LinkedIn
Saniona is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline ...See details»
Saniona - Crunchbase Company Profile & Funding
Saniona is a research and development company with low burn rate, a world class team and high ambitions.See details»
Saniona AB (LON:0RQJ) Company Profile & Description
4 days ago Company profile for Saniona AB (publ) (LON:0RQJ) with a description, list of executives, contact details and other key facts.See details»
Saniona Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Saniona has 5 employees across 3 locations and kr16.84 m in annual revenue in FY 2023. See insights on Saniona including office locations, competitors, revenue, financials, …See details»
Saniona - businessabc.net
Feb 25, 2025 Saniona was founded in 2004 by two scientists from the Technical University of Denmark. The company’s first project was to develop treatments for ADHD and related CNS …See details»
Saniona AB - Drug pipelines, Patents, Clinical trials
May 7, 2025 Explore Saniona AB with its drug pipeline, therapeutic area, technology platform, 9 clinical trials, 61 news, Disease Domain:Nervous System Diseases, Immune System Diseases, Technology Platform:Small molecule …See details»
Investor Relations - Saniona
Saniona is a clinical-stage biopharmaceutical company focused discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders It’s internal pipeline includes SAN2219 for epilepsy and SAN2465 …See details»
Saniona AB - Company Profile and News - Bloomberg Markets
Company profile page for Saniona AB including stock price, company news, executives, board members, and contact informationSee details»
Saniona Announces Strategic Program Prioritization and
Mar 29, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced a strategic program reprioritization and restructuring intended …See details»
Acadia Pharmaceuticals Announces Exclusive License Agreement …
Nov 26, 2024 Acadia will lead further clinical development, regulatory submissions, and global commercialization efforts for SAN711 while also providing financial support for Saniona’s …See details»
Saniona — Broad pipeline to address neurological conditions
Apr 10, 2025 Saniona is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Strong cash position provides operational flexibility to advance broad …See details»
Saniona’s Joint Venture, Cephagenix, Secures Seed Funding from …
Jan 15, 2025 Saniona’s Joint Venture, Cephagenix, Secures Seed Funding from AdBio Partners and AbbVie Ventures Saniona, a clinical-stage biopharmaceutical company, today announces …See details»
Our Science - Saniona
Apr 19, 2020 The Saniona research team has leveraged our expertise and our proprietary methods to design a robust ion channel drug discovery engine and generate a library now …See details»
Vision, Mission, Values - Saniona
Our Vision: Improve the lives of rare disease patients around the world through scientific innovation. Our Mission: We leverage our ion channel targeting expertise to discover, develop …See details»
Working with Us - Saniona
We support our employees with comprehensive benefits and innovative approaches to helping them achieve work-life balance. We look for opportunities for every member of our team to …See details»
Our Pipeline - Saniona
Saniona’s Pipeline What does it take to develop a drug? What is a clinical trial? What are the phases of clinical development? And how is this process sometimes different for rare …See details»
Saniona Announces Strategic Program Prioritization and …
Mar 29, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced a strategic program reprioritization and restructuring intended …See details»
Saniona's CEO comments on the billion dollar deal - Biostock
SAN2355 is Saniona's preclinical, highly selective activator of Kv7.2/Kv7.3 potassium channels – a validated mechanism for seizure suppression – designed to overcome the off-target side …See details»
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with …
3 days ago Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for …See details»
Jazz pays Saniona $42.5M to add prospect to epilepsy ensemble
3 days ago Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a preclinical asset designed to address problems faced by …See details»